Clinical Trial

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the combination of Rezvilutamide and ADT.
Trial Details
NCT Number NCT05983783
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect
Enrollment 200 participants
Start Date 2023-08-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-09